Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming March 23, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Geron Corporation (Geron or the Company) (NASDAQ: GERN) investors who purchased common stock March 19, 2018 and September 26, 2018, inclusive (the Class Period).
If you are a shareholder who suffered a loss, click here to participate.
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to email@example.com, or visit our website at www.glancylaw.com.
On March 27, 2018, STAT published a report revealing that the Companys recent stock performance was due to flimsy claims in connection to the efficacy of imetelstat, Gerons experimental myelofibrosis treatment. STAT stated that the available data for imetelstat undercuts Gerons representations as to the drugs efficacy.
On this news, Gerons share price fell $1.75, or over 29%, over two consecutive trading sessions to close at $4.23 per share on March 27, 2018, thereby injuring investors.
Then, on September 27, 2018, Geron disclosed its Phase 2 study results for imetelstat failed to meet its primary efficacy endpoints.
On this news, Gerons share price fell $3.92, or over 62%, to close at $2.31 per share on September 27, 2018, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company had misled investors about the clinical study results for imetelstat; and (2) that as a result, Defendants statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased or otherwise acquired Geron common stock during the Class Period, you may move the Court no later than March 23, 2020 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.